Adrian Vella, MD; Piet C. de Groen, MD; Sean F. Dinneen, MD, MSc
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Vella A, de Groen PC, Dinneen SF. Fatal Hepatotoxicity Associated with Troglitazone. Ann Intern Med. 1998;129:1080. doi: 10.7326/0003-4819-129-12-199812150-00032
Download citation file:
Published: Ann Intern Med. 1998;129(12):1080.
TO THE EDITOR:
We read with interest Dr. Whitcomb's letter concerning, among other issues, hepatotoxicity associated with troglitazone . According to experience in clinical trials to date, troglitazone-related hepatotoxicity is usually asymptomatic, mild, and reversible. However, clinical trial experience of drug toxicity often underestimates the prevalence and severity of adverse events observed during postmarketing use . News of six deaths and one liver transplantation associated with troglitazone led to withdrawal of the product from the British market . We describe another case of fatal hepatitis associated with troglitazone.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only